Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

February 5, 2024

https://www.globenewswire.com/news-release/2024/02/05/2823572/0/en/Cogent-Biosciences-to-Present-SUMMIT-Part-1b-Data-with-Bezuclastinib-in-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-2024-AAAAI-Annual-Meeting.html

WALTHAM, Mass. and BOULDER, Colo., Feb. 05, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its upcoming posters for bezuclastinib at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Washington, D.C. from February 23-26, 2024. The company will host a virtual investor webcast on Friday, February 23 at 8:00 a.m. ET.

Read more at globenewswire.com

Related news for (COGT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.